Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study

MLA

Ming‐Hao Xu, et al. “Effectiveness and Safety of Lenvatinib plus Anti‐programmed Death‐1 Antibodies in Patients with Hepatocellular Carcinoma: A Real‐world Cohort Study.” Cancer Medicine, vol. 12, no. 8, Apr. 2023, pp. 9202–12. EBSCOhost, https://doi.org/10.1002/cam4.5661.

APA

Ming‐Hao Xu, Cheng Huang, Mei‐Ling Li, Xiao‐Dong Zhu, Chang‐Jun Tan, Jian Zhou, Jia Fan, Hui‐Chuan Sun, & Ying‐Hao Shen. (2023). Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study. Cancer Medicine, 12(8), 9202–9212. https://doi.org/10.1002/cam4.5661

Chicago

Ming‐Hao Xu, Cheng Huang, Mei‐Ling Li, Xiao‐Dong Zhu, Chang‐Jun Tan, Jian Zhou, Jia Fan, Hui‐Chuan Sun, and Ying‐Hao Shen. 2023. “Effectiveness and Safety of Lenvatinib plus Anti‐programmed Death‐1 Antibodies in Patients with Hepatocellular Carcinoma: A Real‐world Cohort Study.” Cancer Medicine 12 (8): 9202–12. doi:10.1002/cam4.5661.